According to a recent LinkedIn post from Viome, the company is emphasizing a shift in microbiome testing from simple taxonomic profiling toward assessing gene expression and metabolic activity. The post contrasts DNA-based identification of which microbes are present with RNA-based insight into which microbes are actively influencing physiological outcomes.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests that Viome is positioning its platform around “functional biology,” highlighting metatranscriptomics as a core capability for precision health and personalized nutrition. For investors, this focus may indicate a strategy to differentiate Viome in a crowded microbiome and biotechnology market by offering clinically relevant insights, potentially supporting premium pricing, partnerships with healthcare or wellness providers, and longer-term data-driven product development.
By framing microbial behavior and activity as more important than microbial quantity, the post implies that Viome aims to move its offerings closer to actionable health outcomes rather than generic wellness reporting. If this approach yields stronger clinical validation and customer retention, it could enhance the company’s competitive moat and strengthen its position in the growing precision health and diagnostics segment.